Clin Endosc.  2016 May;49(3):235-240. 10.5946/ce.2015.096.

Current Guidelines in the Management of Upper Gastrointestinal Subepithelial Tumors

• Cho JW
• Korean ESD Study Group

• KMID: 2165018
• DOI: http://doi.org/10.5946/ce.2015.096

Abstract

Subepithelial tumors are frequently found in asymptomatic patients in Japan and Korea where cancer screening tests routinely include endoscopy. Most lesions are asymptomatic and clinically insignificant. However, carcinoid tumors, lymphomas, glomus tumor and gastrointestinal stromal tumors (GISTs) are malignant or have the potential to become malignant. Inflammation due to parasitic infestation by Anisakis and poorly differentiated adenocarcinomas in the stomach rarely present as subepithelial lesions. In contrast to the frequency of gastric GIST in the gastrointestinal system, they are uncommon in the duodenum and very rare in the esophagus. The prognosis of patients with GISTs in the stomach is relatively good compared with GISTs in other organs. Along with the location of the tumor, its size and mitotic count are major factors that determine the malignant potential of GIST. Small (<2 cm) asymptomatic GISTs usually have benign clinical course. GIST is the most common subepithelial tumor to occur in the stomach. Although various methods are employed to diagnose GISTs, the risk of GIST metastasis cannot be accurately predicted before lesions are completely resected. Recently, new endoscopic diagnostic methods and treatment techniques have been developed that allow the diagnosis and resection of lesions located in the muscularis propria, without any complications. These endoscopic methods have different indications depending on regions where they are performed.

Keyword

Stomach neoplasms; Gastrointestinal stromal tumors; Endosonography

MeSH Terms

Adenocarcinoma
Anisakis
Carcinoid Tumor
Diagnosis
Duodenum
Early Detection of Cancer
Endoscopy
Endosonography
Esophagus
Gastrointestinal Stromal Tumors
Glomus Tumor
Humans
Inflammation
Japan
Korea
Lymphoma
Neoplasm Metastasis
Prognosis
Stomach
Stomach Neoplasms

Figure

• 

  Fig. 1. Gastric gastrointestinal stromal tumor (GIST) with rapid growing. (A) Endoscopy didn’t detect any mass in the stomach. (B) Four years later, endoscopy showed round smooth elevated mass in gastric angle. (C, D) Enodoscopic subtumorial resection was performed. Tumor size was 1.7 cm. Microscopic finding. GIST with spindle cell type had 7 mitoses/50 high powered fields. H&E stain (E, ×200) was done, and immunohistochemical stains were for positive for c-kit (F, ×200) and CD34 (G, ×200).

• 

  Fig. 2. Algorithm in endoscopic approach to gastric subepithelial tumor. EUS, endoscopic ultrasonography; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection; FNA, fine needle aspiration. a)Malignant features on endoscopy: irregular border, or tumorous ulcer; b)High risk features on EUS: anechoic area, echogenic foci, irregular border, or regional lymph node swelling.

Reference

1. Lim YJ, Son HJ, Lee JS, et al. Clinical course of subepithelial lesions detected on upper gastrointestinal endoscopy. World J Gastroenterol. 2010; 16:439–444.

2. Gill KR, Camellini L, Conigliaro R, et al. The natural history of upper gastrointestinal subepithelial tumors: a multicenter endoscopic ultrasound survey. J Clin Gastroenterol. 2009; 43:723–726.

3. Kim MY, Jung HY, Choi KD, et al. Natural history of asymptomatic small gastric subepithelial tumors. J Clin Gastroenterol. 2011; 45:330–336.

4. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006; 37:1527–1535.

5. Agaimy A, Wünsch PH, Dirnhofer S, Bihl MP, Terracciano LM, Tornillo L. Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol. 2008; 32:867–873.

6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23:70–83.

7. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39:1411–1419.

8. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29:52–68.

9. Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005; 117:289–293.

10. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33:459–465.

11. Trupiano JK, Stewart RE, Misick C, Appelman HD, Goldblum JR. Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol. 2002; 26:705–714.

12. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer. 2005; 103:821–829.

13. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010; 8(Suppl 2):S1–S41.

14. Lachter J, Bishara N, Rahimi E, Shiller M, Cohen H, Reshef R. EUS clarifies the natural history and ideal management of GISTs. Hepatogastroenterology. 2008; 55:1653–1656.

15. Khashab MA, Pasricha PJ. Conquering the third space: challenges and opportunities for diagnostic and therapeutic endoscopy. Gastrointest Endosc. 2013; 77:146–148.

16. Meesters B, Pauwels PA, Pijnenburg AM, Vlasveld LT, Repelaer van Driel OJ. Metastasis in a benign duodenal stromal tumour. Eur J Surg Oncol. 1998; 24:334–335.

17. Nishida T, Kawai N, Yamaguchi S, Nishida Y. Submucosal tumors: comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors. Dig Endosc. 2013; 25:479–489.

18. ASGE Standards of Practice Committee, Gan SI, Rajan E, et al. Role of EUS. Gastrointest Endosc. 2007; 66:425–434.

19. Hwang JH, Saunders MD, Rulyak SJ, Shaw S, Nietsch H, Kimmey MB. A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses. Gastrointest Endosc. 2005; 62:202–208.

20. Karaca C, Turner BG, Cizginer S, Forcione D, Brugge W. Accuracy of EUS in the evaluation of small gastric subepithelial lesions. Gastrointest Endosc. 2010; 71:722–727.

21. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000; 46:88–92.

22. Dumonceau JM, Polkowski M, Larghi A, et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2011; 43:897–912.

23. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii21–iii26.

24. Nishida T, Hirota S, Yanagisawa A, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008; 13:416–430.